Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): C Noah Nilsson , Mads Kristian Ersbøll , Finn Gustafsson Added: 8 months ago

Heart Failure
HFA 23: REDWOOD-HCM-Cohort 4: Aficamten in symptomatic nHCM
Author(s): Ahmad Masri Added: 1 year ago
ESC-HFA 23 — We are joined by Dr Ahmad Masri (Oregon Health & Science University Medical Group, US) to discuss the findings from REDWOOD-HCM cohort 4 (NCT04219826). This study assessed the safety and tolerability of the selective inhibitor of cardiac myosin, aficamten (Cytokinetics) in patients with symptomatic nHCM. Cohort 4 included 41 patients. The data presented at HFA 23 shows that… View more

Heart Failure
AHA 24: The REMS Program for Mavacamten
Author(s): Milind Y Desai Added: 5 months ago
AHA Conference 2024 - 22 month data from the risk evaluation and mitigation strategy (REMS) program for mavacamten (Camzyos; Bristol-Myers Squibb Company) in hypertrophic cardiomyopathy (HCM) patients.Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at AHA Conference to discuss the findings from the REMS program for mavacamten.The REMS program investigated the safety and efficacy of… View more

Heart Failure
2023 ESC Guidelines Update: Acute & Chronic Heart Failure
Author(s): Giuseppe Rosano , Harriette Van Spall Added: 1 year ago
ESC 23 – Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Prof Giuseppe Rosano (St George’s Hospitals NHS Trust University of London, UK), President of HFA to distil the key messages from the 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Prof Rosano summarises the retained ejection fraction… View more

Guidelines & Statements

Heart Failure
ESC – Heart Failure Guideline Review
Author(s): Carolyn Lam , Giuseppe Rosano Added: 1 year ago
In this short video series, recorded at ESC 2023 in Amsterdam,Prof Carolyn Lam(National Heart Centre Singapore, SG) and Prof Giuseppe Rosano(St George’s University Medical School of London, UK) discuss the latest heart failure guideline updates and what this means for clinical practice. Since the publication of the 2021 ESC Guidelines, several randomised controlled trials have provided… View more

Guidelines & Statements

Heart Failure
Kevin Damman
Research Area(s) / Expertise:

Heart Failure

Imaging & Diagnostics

 Job title: Head of the Heart Transplant and Left Ventricular Device Program
Dr Kevin Damman is Head of the Heart Transplant and Left Ventricular Device Program at the University Medical Center Groningen in the Netherlands. His research interests focus on acute and advanced heart failure, including cardiorenal axis. He is also interested in improving the treatment of acute heart failure patients, with early assessment of decongestive therapies, SGLT2 inhibitors in… View more
EMPA-KIDNEY: Empagliflozin in Patients with Chronic Kidney Disease
Author(s): William Herrington Added: 6 months ago
Long-term cardio-renal outcomes investigating empagliflozin (Boehringer Ingelheim) on kidney disease progression (KDP) or cardiovascular death in patients with pre-existing chronic kidney disease.In this short interview, Prof William Herrington (Nuffield Department of Population Health, University of Oxford, Oxford, UK) discusses the findings from EMPA-KIDNEY (NCT03594110).EMPA-KIDNEY is an… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
AHA 24: The EMPEROR-Preserved Trial
Author(s): Andrew JS Coats Added: 5 months ago
AHA Conference 2024 - Discover the findings from a new study on the impact of diastolic dysfunction on the efficacy of empagliflozin in heart failure in the EMPEROR-Preserved trial.Prof Andrew Coats (Heart Research Institute, New South Wales, AU) joins us onsite at AHA Conference to discuss findings from a new analysis of diastolic dysfunction in the EMPEROR-Preserved trial (NCT03057951).EMPEROR… View more

Heart Failure
An Expert Approach to Cardio-Renal Protection in CKD: Part Two
Author(s): James Burton Added: 1 year ago
Chaired by Prof James Burton (University of Leicester, UK), this roundtable features expert insight from a world-renowned faculty, Prof David Wheeler (University College London, UK) and Dr Navdeep Tangri (University of Manitoba, CA).Dr Tangri begins by providing an overview of the recent KDIGO guideline updates. Following this, the panel recap on the patient case that was presented in part one of… View more

Heart Failure

Prevention & Chronic Conditions
ACC 24 Late-Breaker Discussion: The ARISE-HF Trial
Author(s): Harriette Van Spall , James L Januzzi Added: 1 year ago
ACC 2024 — Late-breaker host Dr Harriette Van Spall (McMaster University, CA) sits down with Dr James L. Januzzi (Massachusetts General Hospital & Harvard Medical School, US) to discuss the latest findings from the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure trial (ARISE-HF, Applied Therapeutics, Inc) (NCT04083339).This phase 3 multicenter, randomized,… View more

Heart Failure

Prevention & Chronic Conditions